Summary
Acute i.v. infusion but not daily oral administration of thioridazine-HCl in the dog produced EKG anomalies similar to those reported in psychiatric patients taking this drug. Lack of EKG effects after thioridazine-5-sulfoxide infusion and presence of anomalies after thioridazine at equivalent doses suggests further evaluation of the relationship between reported plasma levels of thioridazine and its ring-sulfoxide in association with EKG changes.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
H. G. Kelly, J. E. Fay and S. G. Laverty, Can. med. Ass. J.89, 546 (1963).
T. A. Ban and A. St. Jean, Can. med. Ass. J.91, 537 (1964).
R. L. Dillenkoffer, R. B. George, M. P. Bishop and D. M. Gallant, in: Advances in Biochemical Psychopharmacology, vol. 9, p. 487. Ed. I. S. Forrest, C. J. Carr and E. Usdin. Raven Press, New York 1974.
R. Axelsson, Curr. ther. Res.21, 587 (1977).
E. C. Dinovo, L. A. Gottschalk, R. Biener and B. R. Nandi, Proc. west. Pharmac. Soc.21, 311 (1978).
L. J. Traficante, B. Hine, S. Gershon and G. Sakalis, Commun. Psychopharmac.1, 407 (1977).
Author information
Authors and Affiliations
Additional information
This study was supported, in part, by a Grant-in-Aid from Boehringer-Ingelheim, Ltd. Sandoz, Inc. kindly provided thioridazine HCl (Mellaril®) and thioridazine-5-sulfoxide.
Rights and permissions
About this article
Cite this article
Hine, B., Traficante, L.J., Sakalis, G. et al. Thioridazine and EKG anomalies. Experientia 35, 1631–1632 (1979). https://doi.org/10.1007/BF01953235
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01953235